CLSA said that Vedanta Ltd's Q2 FY26 EBITDA was in line with expectations and that the company is guiding for FY26 EBITDA of over $6 billion, supported by higher commodity prices and operational gains ...
The preliminary decision to block Cosette's acquisition of Mayne Pharma sets a bad precedent and would weaken Australia's capital markets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback